TrippBio, Inc.
PrivateLast Round
Seed
Nov 30, 2022
Total Funding Raised
$3.08M
Company Overview
TrippBio, Inc. is a biotechnology company that develops antiviral treatments by repurposing existing drugs to treat infectious diseases such as COVID-19, influenza, and RSV.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
TrippBio, Inc. Comparables
Compare TrippBio, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Atriva Therapeutics GmbH | 78% | |
| Altesa BioSciences | 77% | |
| Cocrystal Pharma Inc | 66% | |
TrippBio, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed | Nov 30, 2022 | ||||
| Crowdfunding | Jan 29, 2021 | ||||
| Seed | Sep 22, 2020 |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 4, 2026
Monthly visitors grew 128% MoM.
- Jan 29, 2021
$185K raised in a crowdfunding round.
TrippBio, Inc. Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about TrippBio, Inc.'s valuation, stock price, and market status.